HAL (France)
open access
Allele burden expansion in <i>JAK2</i> <sup>V617F</sup> and <i>CALR</i> ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment
Recent prospective studies demonstrated that reductions in JAK2 V617F variant allele frequency (VAF) correlate with clinical benefit in essential thrombocythemia (ET) and polycythemia vera (PV). 1,2 However, the impact of CALR VAF dynamics with therapy on clinical outcomes remains relatively
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma#917418
- Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis#801417
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms#982345
- A Study of MCARH109 and MCARH125 in People With Multiple Myeloma#899527
- EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway#379314
Record · ID 1000761
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive